Fig 1: Virus-Specific T Cells Accumulate in WATVirus-specific T cells in adipose tissue and spleen were quantified at multiple times after acute infection by tetramer staining and ICCS.(A) Representative dot plots identify DbGP33+CD8+ T cells (left) and IAbGP67+CD4+ T cells (right) before infection and at days 8 and 70 post infection. The numbers indicate the frequency of the tetramer+ cells among all live cells in the spleen or among leukocytes isolated from the fat pads.(B) The number (mean ± SEM) of tetramer-positive T cells per spleen or fat pads at the indicated times post-infection. Data are drawn from two independent experiments with three to five mice per group.(C) Representative dot plots show GP33-specific CD8+ T cells or GP61-specific CD4+ T cells expression of IFNg after peptide stimulation. The analyses are from the indicated days after infection, with numbers indicating the percentage of IFNg+ cells among all cells.(D) The number (mean ± SEM) of IFNg+ epitopespecific T cells per tissue in spleen and fat pads as measured using ICCS assay at the indicated times post-infection. Data represent two experiments with five to nine mice per group.(E) T cell co-expression of IFNg with TNF or IFNg with IL-2 in the spleen or fat pads at day 8. CD8+ T cells were stimulated with GP33–41 peptide;CD4+ T cells were stimulated with GP61–80 peptide.See also Figure S1.
Fig 2: Pyrrothiogatain inhibits Th2 cell differentiation and production of Th2 cytokines. (A) Intracellular staining of IL-5/IL-13, IL-4/IFN-γ, and IL-2/IFN-γ in naive CD4+ T cells cultured under Th2 conditions in the presence or absence of pyrrothiogatain (30 and 80 µM) for five days. (B) Cytokine production induced in the pyrrothiogatain treated Th2 cells shown in panel (A) was determined by ELISA. (C) Quantitative RT-PCR analysis of the pyrrothiogatain-treated Th2 cells shown in panel (A). (D) Immunoblot analysis of GATA3 in naive CD4+ T cells cultured under Th2 conditions in the presence or absence of pyrrothiogatain (80 µM) for 5 days. (E) Cytokine production from Th2 cells stimulated with immobilized anti-TCRβ mAb for 16 h in the presence or absence of pyrrothiogatain (0 to 100 µM). The amounts of IL-4, IL-5 and IL-13 in the culture supernatants were determined by ELSA. In (B), (C) and (E), all data are expressed as individual points of three independent experiments with error bars indicating standard deviation.
Fig 3: H1Y98F-VLP elicits robust CD4+ T cell responses with enhanced recruitment of antigen-specific CD4+ T cells to the bone marrow.Splenocytes and BM immune cells were stimulated for 18 h with 2.5 µg/ml H1WT-VLP. Flow cytometry was used to quantify H1-specific CD4+ T cells in a splenocytes isolated at 28 days post-vaccination (3 µg) and in b splenocytes and c BM immune cells at 28 days post-boost (0.5 µg/dose). Background values obtained from non-stimulated samples were subtracted from values obtained following stimulation with H1WT-VLP. a–c The left panel shows the mean frequency (±SEM) of CD4+ T cells expressing CD44 and at least one of IL-2, TNFα or IFNγ. The right panel shows the individual cytokine signatures of responding CD4+ T cells obtained by Boolean analysis. Color-matched pie charts depict relative distributions of cytokine-producing CD4+ T cell populations and IFNγ+ populations are highlighted by a green arc. Statistical significance was determined by Kruskal–Wallis test with Dunn’s multiple comparisons (total response) or two-way ANOVA with Tukey’s multiple comparisons (cytokine signatures) (*p < 0.033, **p < 0.01, ***p < 0.001). Spearman’s rank correlation technique was applied to evaluate the relationship between (d) the frequency of H1-specific CD4+ T cells in the spleen and BM, e the frequency of IL-2+TNFα+IFNγ- CD4+ T cells in the spleen and IgG avidity index (4 M urea) and f the frequency of IL-2+TNFα+IFNγ− CD4+ T cells in the BM and HI titer (*p < 0.033, **p < 0.01).
Fig 4: Minihepcidin-Mediated Serum Iron Deficiency Inhibits the CD8 T Cell Response to a Diverse Range of Immunizations and Impairs the Quality of CD4 T Cell Responses.(A) Experimental scheme to examine effect of minihepcidin injection on immunization.(B) Antigen-specific T cell populations quantified by flow cytometry 7 days after immunization. Left to right: number of splenic endogenous OVA-specific CD8 T cells after AdHu5-OVA immunization, frequency of endogenous OVA-specific CD8 T cells as a percentage of total CD8s in peripheral blood after AdHu5-OVA immunization, number of splenic OT-I OVA-specific CD8 T cells after MVA-OVA immunization, number of splenic OT-I OVA-specific CD8 T cells after OVA and adjuvant immunization, and frequency of endogenous vaccinia (B8R epitope)-specific CD8 T cells as a percentage of total CD8s, resolved by IFN? production after ex vivo peptide restimulation, induced by MVA-OVA immunization. Means ± SDs. t test. Student’s 2-tailed t test, unpaired.(C) Left to right: relative MFI of IFN? and TNF-a for OT-I effector cells producing the respective cytokine, MFI normalized to average of vehicle group; percentage of OT-I effector cells that secrete IL-2. Cytokine-producing cells resolved by intracellular cytokine staining after ex vivo restimulation of splenocytes from mice with SIINFEKL peptide 7 days after MVA-OVA immunization. Means ± SDs. t test. Student’s 2-tailed t test, unpaired.(D) Frequency of endogenous vaccinia-specific IFN?, TNF-a, or IL-2 producing CD40L+ CD4 Th1 effector T cells as a percentage of total CD4s, resolved by intracellular cytokine staining after ex vivo restimulation of splenocytes with MVA-OVA-pulsed dendritic cells. Means ± SDs. t test. Student’s 2-tailed t test, unpaired.(E) Number of splenic OT-II T follicular helper cells induced by OVA and adjuvant immunization. Frequency of splenic TNF-a+ and IL-2+ OT-II effector cells induced by OVA and adjuvant immunization as a percentage of total OT-II CD4 T cells after ex vivo restimulation with peptide. Frequency of splenic GC B cells as a percentage of B cells after OVA and adjuvant immunization. All 7 days post-immunization. Means ± SDs. t test. Student’s 2-tailed t test, unpaired.
Fig 5: Aiolos deficiency results in acquisition of cytotoxic features by CD4 T cells in vivo.Naïve WT or Aiolos-deficient (Ikzf3-/-) mice were infected intranasally with 30 PFU influenza (A/PR8/34; “PR8”). After 8 days, draining lymph nodes (DLN) were harvested and viable CD4+ effector populations were analyzed via flow cytometry. a–c Analysis of of T-bet and Eomes expression by influenza nucleoprotein (NP)-specific CD4+. Data are compiled from 7 independent experiments (n = 22 ± s.e.m; **P < 0.01; two-sided, unpaired Student’s t test). d Single-cell suspensions from the DLN were incubated in culture medium in the presence of protein transport inhibitors for 3 h. Perforin production by Eomes+ populations was analyzed via flow cytometry. Data are compiled from four independent experiments (n = 11 ± s.e.m; *P < 0.05, **P < 0.01; two-sided, unpaired Student’s t test). e CD4+ NP-specific cells were enumerated. Data are compiled from 7 independent experiments (n = 22 ± s.e.m; *P < 0.05; two-sided, unpaired Student’s t test). f CD25 (IL-2Ra) surface expression was evaluated on viable antigen-specific CD4+CD44+CD62L-Foxp3- (effector) T cells from the lung-draining lymph nodes (DLN) via flow cytometry. Percentage of CD25+ cells are shown. Data are compiled from three independent experiments (n = 9 ± s.e.m; **P < 0.01, ****P < 0.0001; two-sided, unpaired Student’s t test). g Production of IL-2 by CD4+ T cell populations was analyzed in WT vs. Aiolos-deficient cells from the DLN by flow cytometry. Cells were cultured in the presence of PMA and Ionomycin and protein transport inhibitors for 3 h prior to analysis. Data are compiled from two independent experiments (n = 7 ± s.e.m; two-sided, unpaired Student’s t test). Source data are provided as a Source Data file.
Supplier Page from BioLegend for APC anti-mouse IL-2